Metabolomics: a promising diagnostic and therapeutic implement for breast cancer

References

• Wishart DS. Current progress in computational metabolomics. Brief Bioinform. 2007;8(5):279–293. doi:10.1093/bib/bbm03017626065
   PubMed Web of Science ®Google Scholar
• Gates SC, Sweeley CC. Quantitative metabolic profiling based on gas chromatography. Clin Chem. 1978;24(10):1663–1673.359193
   PubMed Web of Science ®Google Scholar
• Yan M, Qi H, Xia T, et al. Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKalpha. Metabolism. 2019;91:18–29. doi:10.1016/j.metabol.2018.11.01030468782
   PubMed Web of Science ®Google Scholar
• Preti G. Metabolomics comes of age? The Scientist. 2005;19(11):8.
   Google Scholar
• Patti GJ, Yanes O, Siuzdak G. Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263–269. doi:10.1038/nrm331422436749
   PubMed Web of Science ®Google Scholar
• Jagannathan NR, Sharma U. Breast tissue metabolism by magnetic resonance spectroscopy. Metabolites. 2017;7:2. doi:10.3390/metabo7020025
   Web of Science ®Google Scholar
• Hadi NI, Jamal Q, Iqbal A, Shaikh F, Somroo S, Musharraf SG. Serum metabolomic profiles for breast cancer diagnosis, grading and staging by gas chromatography-mass spectrometry. Sci Rep. 2017;7(1):1715. doi:10.1038/s41598-017-01924-928496143
   PubMedGoogle Scholar
• Harvie MN, Sims AH, Pegington M, et al. Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. Breast Cancer Res. 2016;18(1):57. doi:10.1186/s13058-016-0714-427233359
   PubMedGoogle Scholar
• Cavaco C, Pereira JAM, Taunk K, et al. Screening of salivary volatiles for putative breast cancer discrimination: an exploratory study involving geographically distant populations. Anal Bioanal Chem. 2018;410(18):4459–4468. doi:10.1007/s00216-018-1103-x29732495
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Zaimenko I, Lisec J, Stein U, Brenner W. Approaches and techniques to characterize cancer metabolism in vitro and in vivo. Biochimica Et Biophysica Acta Rev Cancer. 2017;1868(2):412–419. doi:10.1016/j.bbcan.2017.08.004
   PubMed Web of Science ®Google Scholar
• Cardoso MR, Santos JC, Ribeiro ML, Talarico MCR, Viana LR, Derchain SFM. A metabolomic approach to predict breast cancer behavior and chemotherapy response. Int J Mol Sci. 2018;19:2. doi:10.3390/ijms19020617
   Web of Science ®Google Scholar
• Haukaas TH, Euceda LR, Giskeodegard GF, Bathen TF. Metabolic portraits of breast cancer by HR MAS MR spectroscopy of intact tissue samples. Metabolites. 2017;7:2. doi:10.3390/metabo7020018
   Web of Science ®Google Scholar
• Denkert C, Bucher E, Hilvo M, et al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med. 2012;4(4):37.22546809
   PubMedGoogle Scholar
• Fiehn O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp Funct Genomics. 2001;2(3):155–168. doi:10.1002/cfg.8218628911
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang A, Qiu S, Yang S, Wang X. Current trends and innovations in bioanalytical techniques of metabolomics. Crit Rev Anal Chem. 2016;46(4):342–351. doi:10.1080/10408347.2015.107947526337255
   PubMed Web of Science ®Google Scholar
• Markley JL, Bruschweiler R, Edison AS, et al. The future of NMR-based metabolomics. Curr Opin Biotechnol. 2017;43:34–40. doi:10.1016/j.copbio.2016.08.00127580257
   PubMed Web of Science ®Google Scholar
• Nassar AF, Wu T, Nassar SF, Wisnewski AV. UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research. Drug Discov Today. 2017;22(2):463–470. doi:10.1016/j.drudis.2016.11.02027919805
   PubMed Web of Science ®Google Scholar
• Ramautar R. Capillary electrophoresis-mass spectrometry for clinical metabolomics. Adv Clin Chem. 2016;74:1–34. doi:10.1016/bs.acc.2015.12.00227117659
   PubMed Web of Science ®Google Scholar
• Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 2004;22(5):245–252. doi:10.1016/j.tibtech.2004.03.00715109811
   PubMed Web of Science ®Google Scholar
• Kim HK, Choi Yh Fau - Verpoorte R, Verpoorte R. NMR-based Plant Metabolomics: Where Do We Stand, Where Do We Go?Trends in biotechnology. 2011;29(6):267–275. doi:10.1016/j.tibtech.2011.02.001
   Google Scholar
• Karaman I. Preprocessing and pretreatment of metabolomics data for statistical analysis. Adv Exp Med Biol. 2017;965:145–161. doi:10.1007/978-3-319-47656-8_628132179
   PubMedGoogle Scholar
• Wu Y, Li L. Sample normalization methods in quantitative metabolomics. J Chromatogr A. 2016;1430:80–95. doi:10.1016/j.chroma.2015.12.00726763302
   PubMed Web of Science ®Google Scholar
• van Den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics. 2006;7:142. doi:10.1186/1471-2164-7-14216762068
   PubMed Web of Science ®Google Scholar
• Krumsiek J, Bartel J, Theis FJ. Computational approaches for systems metabolomics. Curr Opin Biotechnol. 2016;39:198–206. doi:10.1016/j.copbio.2016.04.00927135552
   PubMed Web of Science ®Google Scholar
• Lind MV, Savolainen OI, Ross AB. The use of mass spectrometry for analysing metabolite biomarkers in epidemiology: methodological and statistical considerations for application to large numbers of biological samples. Eur J Epidemiol. 2016;31(8):717–733. doi:10.1007/s10654-016-0166-227230258
   PubMed Web of Science ®Google Scholar
• Considine EC, Thomas G, Boulesteix AL, Khashan AS, Kenny LC. Critical review of reporting of the data analysis step in metabolomics. Metabolomics. 2017;14(1):7. doi:10.1007/s11306-017-1299-330830321
   PubMed Web of Science ®Google Scholar
• Caesar LK, Kvalheim OM, Cech NB. Hierarchical cluster analysis of technical replicates to identify interferents in untargeted mass spectrometry metabolomics. Anal Chim Acta. 2018;1021:69–77. doi:10.1016/j.aca.2018.03.01329681286
   PubMed Web of Science ®Google Scholar
• Shen J, Yan L, Liu S, Ambrosone CB, Zhao H. Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes. Transl Oncol. 2013;6(6):757–765. doi:10.1593/tlo.1361924466379
   PubMed Web of Science ®Google Scholar
• Audano M, Maldini M, De Fabiani E, Mitro N, Caruso D. Gender-related metabolomics and lipidomics: from experimental animal models to clinical evidence. J Proteomics. 2018;178:82–91. doi:10.1016/j.jprot.2017.11.00129122727
   PubMed Web of Science ®Google Scholar
• Kakkoura MG, Sokratous K, Demetriou CA, et al. Mediterranean diet-gene interactions: a targeted metabolomics study in Greek-Cypriot women. Mol Nutr Food Res. 2017;61:4. doi:10.1002/mnfr.201600558
   Web of Science ®Google Scholar
• Tayyari F, Gowda GAN, Olopade OF, et al. Metabolic profiles of triple-negative and luminal A breast cancer subtypes in African-American identify key metabolic differences. Oncotarget. 2018;9(14):11677–11690. doi:10.18632/oncotarget.2443329545929
   PubMedGoogle Scholar
• Tredwell GD, Miller JA, Chow HH, Thompson PA, Keun HC. Metabolomic characterization of nipple aspirate fluid by (1)H NMR spectroscopy and GC-MS. J Proteome Res. 2014;13(2):883–889. doi:10.1021/pr400924k24364541
   PubMed Web of Science ®Google Scholar
• Veneroni S, Dugo M, Daidone MG, et al. Applicability of under vacuum fresh tissue sealing and cooling to omics analysis of tumor tissues. Biopreserv Biobank. 2016;14(6):480–490. doi:10.1089/bio.2015.009327403896
   PubMedGoogle Scholar
• Haukaas TH, Moestue SA, Vettukattil R, et al. Impact of freezing delay time on tissue samples for metabolomic studies. Front Oncol. 2016;6:17. doi:10.3389/fonc.2016.0001726858940
   PubMed Web of Science ®Google Scholar
• Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698–707. doi:10.1016/j.ctrv.2011.11.00522178455
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci. 2015;36(12):822–846. doi:10.1016/j.tips.2015.08.00926538316
   PubMed Web of Science ®Google Scholar
• Fan Y, Zhou X, Xia TS, et al. Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer. Oncotarget. 2016;7(9):9925–9938. doi:10.18632/oncotarget.715526848530
   PubMedGoogle Scholar
• Jerby L, Wolf L, Denkert C, et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res. 2012;72(22):5712–5720. doi:10.1158/0008-5472.CAN-12-221522986741
   PubMed Web of Science ®Google Scholar
• Budczies J, Brockmoller SF, Muller BM, et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteomics. 2013;94:279–288. doi:10.1016/j.jprot.2013.10.00224125731
   PubMed Web of Science ®Google Scholar
• Cappelletti V, Iorio E, Miodini P, Silvestri M, Dugo M, Daidone MG. Metabolic footprints and molecular subtypes in breast cancer. Dis Markers. 2017;2017:7687851. doi:10.1155/2017/768785129434411
   PubMed Web of Science ®Google Scholar
• Giudetti AM, De Domenico S, Ragusa A, et al. A specific lipid metabolic profile is associated with the epithelial mesenchymal transition program. Biochimica Et Biophysica Acta Mol Cell Biol Lipids. 2019;1864(3):344–357. doi:10.1016/j.bbalip.2018.12.011
   PubMed Web of Science ®Google Scholar
• Winnike JH, Stewart DA, Pathmasiri WW, McRitchie SL, Sumner SJ. Stable isotope-resolved metabolomic differences between hormone-responsive and triple-negative breast cancer cell lines. Int J Breast Cancer. 2018;2018:2063540. doi:10.1155/2018/206354030363973
   PubMed Web of Science ®Google Scholar
• Borgan E, Sitter B, Lingjaerde OC, et al. Merging transcriptomics and metabolomics–advances in breast cancer profiling. BMC Cancer. 2010;10:628. doi:10.1186/1471-2407-10-66321080935
   PubMed Web of Science ®Google Scholar
• Aure MR, Vitelli V, Jernstrom S, et al. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Res. 2017;19(1):44. doi:10.1186/s13058-017-0812-y28356166
   PubMedGoogle Scholar
• Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13(11):1387–1397. doi:10.7150/ijbs.2163529209143
   PubMed Web of Science ®Google Scholar
• Lecuyer L, Victor Bala A, Deschasaux M, et al. NMR metabolomic signatures reveal predictive plasma metabolites associated with long-term risk of developing breast cancer. Int J Epidemiol. 2018;47(2):484–494. doi:10.1093/ije/dyx27129365091
   PubMed Web of Science ®Google Scholar
• Oh H, Coburn SB, Matthews CE, et al. Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women’s Health Initiative Observational Study. Breast Cancer Res. 2017;19(1):28. doi:10.1186/s13058-017-0810-028284224
   PubMedGoogle Scholar
• Moore SC, Playdon MC, Sampson JN, et al. A metabolomics analysis of body mass index and postmenopausal breast cancer risk. J Natl Cancer Inst. 2018;110(6):588–597. doi:10.1093/jnci/djx24429325144
   PubMedGoogle Scholar
• Playdon MC, Ziegler RG, Sampson JN, et al. Nutritional metabolomics and breast cancer risk in a prospective study. Am J Clin Nutr. 2017;106(2):637–649. doi:10.3945/ajcn.116.15091228659298
   PubMed Web of Science ®Google Scholar
• Beger RD, Dunn W, Schmidt MA, et al. Metabolomics enables precision medicine: “A white paper, community perspective”. Metabolomics. 2016;12(9):149. doi:10.1007/s11306-016-1094-627642271
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun T, Cao Y, et al. A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. Onco Targets Ther. 2016;9:1389–1398. doi:10.2147/OTT.S9586227042107
   PubMed Web of Science ®Google Scholar
• Siminska E, Koba M. Amino acid profiling as a method of discovering biomarkers for early diagnosis of cancer. Amino Acids. 2016;48(6):1339–1345. doi:10.1007/s00726-016-2215-227033065
   PubMed Web of Science ®Google Scholar
• Yuan B, Schafferer S, Tang Q, et al. A plasma metabolite panel as biomarkers for early primary breast cancer detection. Int J Cancer. 2019;144(11):2833–2842. doi:10.1002/ijc.3199630426507
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao X, Chou J, et al. Taurine, glutamic acid and ethylmalonic acid as important metabolites for detecting human breast cancer based on the targeted metabolomics. Cancer Biomarkers. 2018. doi:10.3233/CBM-181500
   Web of Science ®Google Scholar
• Liao HW, Chen GY, Wu MS, Liao WC, Lin CH, Kuo CH. Development of a postcolumn infused-internal standard liquid chromatography mass spectrometry method for quantitative metabolomics studies. J Proteome Res. 2017;16(2):1097–1104. doi:10.1021/acs.jproteome.6b0101128067522
   PubMed Web of Science ®Google Scholar
• More TH, RoyChoudhury S, Christie J, et al. Metabolomic alterations in invasive ductal carcinoma of breast: a comprehensive metabolomic study using tissue and serum samples. Oncotarget. 2018;9(2):2678–2696. doi:10.18632/oncotarget.2362629416801
   PubMedGoogle Scholar
• Wu J, Yang R, Zhang L, et al. Metabolomics research on potential role for 9-cis-retinoic acid in breast cancer progression. Cancer Sci. 2018;109(7):2315–2326. doi:10.1111/cas.1362929737597
   PubMed Web of Science ®Google Scholar
• Lipovka Y, Konhilas JP. The complex nature of oestrogen signalling in breast cancer: enemy or ally? Biosci Rep. 2016;36:3. doi:10.1042/BSR20160046
   Web of Science ®Google Scholar
• Okamoto Y, Aoki A, Ueda K, Jinno H. Metabolomic analysis uncovered an association of serum phospholipid levels with estrogen-induced mammary tumors in female ACI/Seg rats. Toxicol Lett. 2018;288:65–70. doi:10.1016/j.toxlet.2018.02.01729454887
   PubMed Web of Science ®Google Scholar
• Cala M, Aldana J, Sanchez J, Guio J, Meesters RJW. Urinary metabolite and lipid alterations in Colombian Hispanic women with breast cancer: a pilot study. J Pharm Biomed Anal. 2018;152:234–241. doi:10.1016/j.jpba.2018.02.00929428809
   PubMed Web of Science ®Google Scholar
• Nam H, Chung BC, Kim Y, Lee K, Lee D. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics. 2009;25(23):3151–3157. doi:10.1093/bioinformatics/btp55819783829
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6(1):78–95. doi:10.1007/s11306-009-0178-y20300169
   PubMed Web of Science ®Google Scholar
• Zhong L, Cheng F, Lu X, Duan Y, Wang X. Untargeted saliva metabonomics study of breast cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Talanta. 2016;158:351–360. doi:10.1016/j.talanta.2016.04.04927343615
   PubMed Web of Science ®Google Scholar
• Takayama T, Tsutsui H, Shimizu I, et al. Diagnostic approach to breast cancer patients based on target metabolomics in saliva by liquid chromatography with tandem mass spectrometry. Clin Chim Acta. 2016;452:18–26. doi:10.1016/j.cca.2015.10.03226523874
   PubMed Web of Science ®Google Scholar
• Mannello F. New horizon for breast cancer biomarker discoveries: what might the liquid biopsy of nipple aspirate fluid hold? Proteomics Clin appli. 2017;11:9–10. doi:10.1002/prca.v11.9-10
   Web of Science ®Google Scholar
• Matos Do Canto L, Marian C, Varghese RS, et al. Metabolomic profiling of breast tumors using ductal fluid. Int J Oncol. 2016;49(6):2245–2254. doi:10.3892/ijo.2016.373227748798
   PubMed Web of Science ®Google Scholar
• Phillips M, Cataneo R, Lebauer C, Mundada M, Saunders C. Breath mass ion biomarkers of breast cancer. J Breath Res. 2017;11(1):5. doi:10.1088/1752-7163/aa549b
   Web of Science ®Google Scholar
• Silva CL, Perestrelo R, Silva P, Tomas H, Camara JS. Volatile metabolomic signature of human breast cancer cell lines. Sci Rep. 2017;7:43969. doi:10.1038/srep4396928256598
   PubMed Web of Science ®Google Scholar
• Roig B, Rodríguez-Balada M, Samino S, et al. Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer. Sci Rep. 2017;7. doi:10.1038/s41598-017-17897-828127057
   PubMedGoogle Scholar
• Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653–683. doi:10.1146/annurev.pharmtox.48.113006.09471518184107
   PubMed Web of Science ®Google Scholar
• Ewens A, Luo L, Berleth E, et al. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res. 2006;66(10):5419–5426. doi:10.1158/0008-5472.CAN-05-396316707470
   PubMed Web of Science ®Google Scholar
• Arminan A, Palomino-Schatzlein M, Deladriere C, et al. Metabolomics facilitates the discrimination of the specific anti-cancer effects of free- and polymer-conjugated doxorubicin in breast cancer models. Biomaterials. 2018;162:144–153. doi:10.1016/j.biomaterials.2018.02.01529448142
   PubMed Web of Science ®Google Scholar
• Miolo G, Muraro E, Caruso D, et al. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016;7(26):39809–39822. doi:10.18632/oncotarget.948927223427
   PubMedGoogle Scholar
• Zhang R, Zhuang X, Zong L, Liu S, Liu Z, Song F. Investigations on the cell metabolomics basis of multidrug resistance from tumor cells by ultra-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2016;408(21):5843–5854. doi:10.1007/s00216-016-9696-427379392
   PubMed Web of Science ®Google Scholar
• Zong L, Pi Z, Liu S, Xing J, Liu Z, Song F. Liquid extraction surface analysis nanospray electrospray ionization based lipidomics for in situ analysis of tumor cells with multidrug resistance. Rapid Commun Mass Spectrom. 2018;32(19):1683–1692. doi:10.1002/rcm.822930003601
   PubMed Web of Science ®Google Scholar
• Borgquist S, Bjarnadottir O, Kimbung S, Ahern TP. Statins: a role in breast cancer therapy? J Intern Med. 2018;284(4):346–357. doi:10.1111/joim.1280629923256
   PubMed Web of Science ®Google Scholar
• Klawitter J, Shokati T, Moll V, Christians U, Klawitter J. Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res. 2010;12(2):R16. doi:10.1186/bcr272220205716
   PubMed Web of Science ®Google Scholar
• Hart CD, Vignoli A, Tenori L, et al. Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicenter population. Clin Cancer Res. 2017;23(6):1422–1431. doi:10.1158/1078-0432.CCR-16-115328082280
   PubMed Web of Science ®Google Scholar
• Keun HC, Sidhu J, Pchejetski D, et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin Cancer Res. 2009;15(21):6716–6723. doi:10.1158/1078-0432.CCR-09-145219861449
   PubMed Web of Science ®Google Scholar
• Arenas M, Rodriguez E, Garcia-Heredia A, et al. Metabolite normalization with local radiotherapy following breast tumor resection. PLoS One. 2018;13(11):e0207474. doi:10.1371/journal.pone.020747430444915
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.02525058905
   PubMed Web of Science ®Google Scholar
• Ezaki T, Nishiumi S, Azuma T, Yoshida M. Metabolomics for the early detection of cisplatin-induced nephrotoxicity. Toxicol Res (Camb). 2017;6(6):843–853. doi:10.1039/c7tx00171a30090547
   PubMed Web of Science ®Google Scholar
• Lyon DE, Starkweather A, Yao Y, et al. Pilot study of metabolomics and psychoneurological symptoms in women with early stage breast cancer. Biol Res Nurs. 2018;20(2):227–236. doi:10.1177/109980041774741129258398
   PubMed Web of Science ®Google Scholar
• Sun Y, Kim JH, Vangipuram K, et al. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2018;171(3):657–666. doi:10.1007/s10549-018-4862-329946863
   PubMed Web of Science ®Google Scholar
• Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 2004;9(1):1–31. doi:10.1080/1354750041000166837915204308
   PubMed Web of Science ®Google Scholar
• Warburg O, Wind F, Negelein E. THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 1927;8(6):519–530. doi:10.1085/jgp.8.6.51919872213
   PubMedGoogle Scholar
• Martinez-Outschoorn UE, Prisco M, Ertel A, et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics. Cell Cycle. 2011;10(8):1271–1286. doi:10.4161/cc.10.8.1533021512313
   PubMed Web of Science ®Google Scholar
• O’Day EM, Idos GE, Hill C, Chen JW, Wagner G. Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells. Onco Targets Ther. 2018;11:6827–6838. doi:10.2147/OTT.S17763930349315
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017;356:j477. doi:10.1136/bmj.j47728246088
   PubMed Web of Science ®Google Scholar
• Baek AE, Yu YA, He S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8(1):864. doi:10.1038/s41467-017-00910-z29021522
   PubMedGoogle Scholar
• Wang S, Chen X, Luan H, et al. Matrix-assisted laser desorption/ionization mass spectrometry imaging of cell cultures for the lipidomic analysis of potential lipid markers in human breast cancer invasion. Rapid Commun Mass Spectrom. 2016;30(4):533–542. doi:10.1002/rcm.746626777684
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee KM, Kim SH, Kwon YJ, Chun YJ, Choi HK. Comparative metabolic and lipidomic profiling of human breast cancer cells with different metastatic potentials. Oncotarget. 2016;7(41):67111–67128. doi:10.18632/oncotarget.1156027564096
   PubMedGoogle Scholar
• Cui M, Wang Q, Chen G. Serum metabolomics analysis reveals changes in signaling lipids in breast cancer patients. Biomed Chromatogr. 2016;30(1):42–47. doi:10.1002/bmc.355626179699
   PubMed Web of Science ®Google Scholar
• Xie H-Y, Shao Z-M, Li D-Q. Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis. Chin J Cancer. 2017;36(1):36. doi:10.1186/s40880-017-0202-y28356139
   PubMedGoogle Scholar
• Kus K, Kij A, Zakrzewska A, et al. Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics. Breast Cancer Res. 2018;20(1):148. doi:10.1186/s13058-018-1075-y30514398
   PubMedGoogle Scholar
• Larkin JR, Dickens AM, Claridge TD, et al. Early diagnosis of brain metastases using a biofluids-metabolomics approach in mice. Theranostics. 2016;6(12):2161–2169. doi:10.7150/thno.1653827924154
   PubMed Web of Science ®Google Scholar
• Krzeszinski JY, Schwaid AG, Cheng WY, et al. Lipid osteoclastokines regulate breast cancer bone metastasis. Endocrinology. 2017;158(3):477–489. doi:10.1210/en.2016-157027967239
   PubMed Web of Science ®Google Scholar
• Auslander N, Yizhak K, Weinstock A, et al. A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer. Sci Rep. 2016;6:29662. doi:10.1038/srep2966227406679
   PubMed Web of Science ®Google Scholar
• Helland T, Henne N, Bifulco E, et al. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017;19(1):125. doi:10.1186/s13058-017-0916-429183390
   PubMedGoogle Scholar
• El Ansari R, McIntyre A, Craze ML, Ellis IO, Rakha EA, Green AR. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 2018;72(2):183–190. doi:10.1111/his.1333428771772
   PubMed Web of Science ®Google Scholar
• Dong J, Xiao D, Zhao Z, et al. Epigenetic silencing of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism. Oncogenesis. 2017;6(7):e356. doi:10.1038/oncsis.2017.5928692032
   PubMedGoogle Scholar
• Cha YJ, Kim ES, Koo JS. Amino acid transporters and glutamine metabolism in breast cancer. Int J Mol Sci. 2018;19:3. doi:10.3390/ijms19030907
   Web of Science ®Google Scholar
• McCartney A, Vignoli A, Biganzoli L, et al. Metabolomics in breast cancer: a decade in review. Cancer Treat Rev. 2018;67:88–96. doi:10.1016/j.ctrv.2018.04.01229775779
   PubMed Web of Science ®Google Scholar
• Coloff JL, Murphy JP, Braun CR, et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab. 2016;23(5):867–880. doi:10.1016/j.cmet.2016.03.01627133130
   PubMed Web of Science ®Google Scholar
• Beatty A, Fink LS, Singh T, et al. Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple-negative breast cancer. Mol Cancer Ther. 2018;17(1):264–275. doi:10.1158/1535-7163.MCT-17-040729021292
   PubMed Web of Science ®Google Scholar
• Teoh ST, Ogrodzinski MP, Ross C, Hunter KW, Lunt SY. Sialic acid metabolism: a key player in breast cancer metastasis revealed by metabolomics. Front Oncol. 2018;8:174. doi:10.3389/fonc.2018.0017429892572
   PubMed Web of Science ®Google Scholar